Indefinite Delivery Contract 75N93018D00008

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to R T I International to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product development...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to the University of Saskatchewan to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to American Type Culture Collection to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables task orders to be issued across five areas: product...

The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...

The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...

This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide preclinical development support for candidate products addressing HIV, HBV, HCV and other infectious diseases. The multiple award ID/IQ contract holds a potential value of $107 million and a period of performance from October 2020 through October 2027. The contract establishes seven task areas for procuring services such as in vitro testing,...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030. Services will be delivered under five task areas: product...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...